Skip to main content

Table 2 Sensitivity, specificity, 95% confidence intervals and likelihood ratios

From: PTPN22polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease

 

Sensitivity

Specificity

Likelihood ratio

 

%

95% CI

%

95% CI

 

PTPN22 CT+TT

39.3

29.6–49.7

80.3

75.9–84.1

2.0

Anti-CCP Abs

37.1

27.5–47.5

98.6

96.9–99.5

26.2

IgG-RF

16.9

8.9–28.1

95.8

92.6–97.8

4.0

IgA-RF

42.4

30.3–55.2

94.9

91.5–97.2

8.3

IgM-RF

22.0

12.8–33.9

94.1

90.5–96.6

3.7

SE (B1*0404 or 0401)

55.6

45.2–65.6

61.8

54.4–68.9

1.5

SE + PTPN22 CT+TT

24.1

16.0–34.0

92.9

88.3–96.1

3.4

Anti-CCP Abs + PTPN22 CT+TT

22.1

14.3–31.8

100.0

-

-

  1. Sensitivity, specificity, 95% confidence intervals (CIs) and likelihood ratios were determined for the presence of the PTPN22 1858T variant (CT+TT), anti-cyclic citrullinated peptide antibodies (anti-CCP Abs), rheumatoid factors IgM-RF, IgG-RF and IgA-RF, and carriage of human leukocyte antigen shared epitope (HLA-SE) in pre-patients and matched controls.